Microsulis Medical Limited (http://www.microsulis.com/) announced this week that it has exclusively licensed to Hologic Inc all rights to its microwave technology in the gynecology and female urology fields of use.
“We look forward to working with Hologic over the next months and years in developing value from our technology portfolio. We are pleased that our customers will continue to be supported by such a capable company.”
From 2007 Microsulis has focused strategically on the development of its breakthrough microwave tumour ablation MTA system. "Following years of investment and technical development in 2010 we achieved CE Mark and FDA 510k clearance on our revolutionary high power Microwave Tumour Ablation (MTA) system. This breakthrough system redefines the performance benchmark for tumour ablation devices in the interventional oncology market. Through the sale of our MEA platform to Hologic, we not only open our microwave technology to the most capable device developer in the woman's health space, but we release the value of MEA to underpin the commercialization phase of our MTA device." commented Microsulis CEO Stuart McIntyre. "Hologic has the capability and market leadership needed to release the potential of our microwave technology to treat various female urological and gynecological conditions. There is no better company to nurture the technology in the woman's health space."
Hologic is the leading supplier of medical devices and products for treating women's health conditions. The NovaSure Endometrial Ablation System is recognized worldwide as a premier product with a long track record of safety and efficacy. "We look forward to working with Hologic over the next months and years in developing value from our technology portfolio. We are pleased that our customers will continue to be supported by such a capable company." said Stuart McIntyre.
A Discussion with Hologic’s Tim Simpson on the Future of Cervical Cancer Screening